CuraGen Corporation.
CuraGen Scientists have developed a deep preclinical pipeline of potential protein, antibody and small molecule therapeutics by integrating expertise in molecular biology with a proprietary suite of functional genomic technologies. One important application of functional genomics is in the area of pharmacogenomics, which has been a critical component in CuraGen's drug discovery and development efforts. By identifying safety and efficacy issues early in the discovery process and by gaining a better understanding of a drug's mechanism of action, CuraGen scientists are able to make more informed decisions about which drugs are the most appropriate to advance through the preclinical and clinical development stages.